Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Bast

Showing results (211-220 of 299) with videos related to

Pageof 30
Sort By:
Gynecologic Oncology|May 1, 1988
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinomaV R Zurawski, R C Knapp, N Einhorn, et al.
Cancer|June 25, 1992
Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibodyM A Deutsch, J C Pence, B J Kerns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumorsD M Gershenson, M Deavers, S Diaz, et al.
Journal of Hematotherapy|February 1, 1996
A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrowJ J Vredenburgh, O Silva, C Tyer, et al.
Cancer|October 25, 1991
Coordinate elevation of serum markers in ovarian cancer but not in benign diseaseR C Bast, S Knauf, A Epenetos, et al.
Gynecologic Oncology|September 1, 1985
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinomaR C Bast, F P Siegal, C Runowicz, et al.
Hybridoma|October 28, 1998
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissuesR C Bast, L Pusztai, B J Kerns, et al.
Chronobiologia|July 11, 1992
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacyG Cornélissen, F Halberg, E Halberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cellsG S Dean, L Pusztai, F J Xu, et al.
International Journal of Cancer|January 15, 1989
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cellsC M Boyer, M J Borowitz, K S McCarty, et al.
Pageof 30

Showing results (211-220 of 299) with videos related to

Sort By:
Pageof 30
Gynecologic Oncology|May 1, 1988
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinomaV R Zurawski, R C Knapp, N Einhorn, et al.
Cancer|June 25, 1992
Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibodyM A Deutsch, J C Pence, B J Kerns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumorsD M Gershenson, M Deavers, S Diaz, et al.
Journal of Hematotherapy|February 1, 1996
A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrowJ J Vredenburgh, O Silva, C Tyer, et al.
Cancer|October 25, 1991
Coordinate elevation of serum markers in ovarian cancer but not in benign diseaseR C Bast, S Knauf, A Epenetos, et al.
Gynecologic Oncology|September 1, 1985
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinomaR C Bast, F P Siegal, C Runowicz, et al.
Hybridoma|October 28, 1998
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissuesR C Bast, L Pusztai, B J Kerns, et al.
Chronobiologia|July 11, 1992
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacyG Cornélissen, F Halberg, E Halberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cellsG S Dean, L Pusztai, F J Xu, et al.
International Journal of Cancer|January 15, 1989
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cellsC M Boyer, M J Borowitz, K S McCarty, et al.
Pageof 30